Stockscreener 앱 받기
263.84
0.89%
-2.44
전일 마감가:
$266.28
열려 있는:
$265.45
하루 거래량:
2.02M
Relative Volume:
0.35
시가총액:
$466.25B
수익:
$62.82B
순이익/손실:
$3.60B
주가수익비율:
130.14
EPS:
2.0274
순현금흐름:
$19.98B
1주 성능:
-0.49%
1개월 성능:
+3.30%
6개월 성능:
+26.03%
1년 성능:
+18.26%
1일 변동 폭
$261.52
$268.93
1주일 범위
$261.52
$269.39
52주 변동 폭
$190.75
$269.39
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
263.85 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,186.18 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.44 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
149.29 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
145.68 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-08-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2026-04-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth - Yahoo Finance
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. - The Motley Fool
AbbVie Inc Hired Firms, 2026 - OpenSecrets
AbbVie Inc Lobbyists, 2026 - OpenSecrets
AbbVie Inc Lobbyists, 2025 - OpenSecrets
Comparative Analysis of AbbVie and Johnson & Johnson in a Shifting Market - Intellectia AI
AbbVie Says Botox Exempt From Medicare Price Negotiations - law360.com
US FDA approves AbbVie's drug for Parkinson's disease - Reuters
US FDA approves AbbVie’s drug for Parkinson’s disease - WTAQ
Investment Outlook Comparison: AbbVie vs. Pfizer - Intellectia AI
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO - Reuters
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade - 24/7 Wall St.
Allergan Aesthetics - WCIV
ADARx Pharmaceuticals raises $446 million in upsized IPO - qz.com
Is AbbVie Inc. (ABBV) Rewriting the Bluechip Stocks Playbook? - Kalkine Media
AbbVie stock nears its record high after a quarterly beat - AD HOC NEWS
ADARx Pharmaceuticals Plans $350 Million IPO with AbbVie Investment - intellectia.ai
AbbVie stock heads into the open after a flat close - ad-hoc-news.de
RBC Capital Sticks to Its Buy Rating for AbbVie (ABBV) - The Globe and Mail
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? - The Globe and Mail
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules - Yahoo Finance
UChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality - PR Newswire
AbbVie And Iambic Partner To Accelerate AI-Driven Drug Discovery In Immunology, Neuroscience And Oncology - Pulse 2.0
AbbVie | 9/24/26 - ktnv.com
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio? - The Globe and Mail
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick? - Zacks Investment Research
What Is AbbVie (NYSE:ABBV) Adding to Healthcare AI Research? - Kalkine Media
AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma - Yahoo Finance
AbbVie stock heads into the open after a 0.02 percent gain - AD HOC NEWS
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade - Yahoo Finance
AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell' (NYSE:ABBV) - Seeking Alpha
AbbVie stock ends the day 0.2 percent higher at USD 266.45 - AD HOC NEWS
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO - Yahoo Finance
What Is AbbVie No Longer Telling You? - Trefis
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie (NYSE:ABBV) - Seeking Alpha
AbbVie stock hits all-time high of 267.48 USD By Investing.com - Investing.com Nigeria
AbbVie stock hits all-time high of 267.48 USD - Investing.com
AbbVie (ABBV) Receives a Buy from Scotiabank - The Globe and Mail
AbbVie stock closes at USD 265.21 as EU approval adds support - AD HOC NEWS
Why is AbbVie (NYSE:ABBV) in focus amid today’s healthcare stocks discussion? - Kalkine Media
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis - Yahoo! Finance Canada
Where does AbbVie (NYSE:ABBV) go as medicine launches shifts? - Kalkine Media
AbbVie stock gains 0.3 percent ahead of the open - AD HOC NEWS
Pediatric Arthritis Treatments: AbbVie Expands RINVOQ to Children With Active pJIA - Trend Hunter
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters - Yahoo Finance
AbbVie stock ends the day higher at USD 265.51 - AD HOC NEWS
AbbVie’s Rinvoq Wins 11th EU Approval in Pediatric Arthritis - AskTraders
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis - Yahoo Finance
New EC approval for AbbVie’s Rinvoq - The Pharma Letter
Is AbbVie (NYSE:ABBV) Stock Worth Watching Today? - Kalkine Media
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.31%
1.79%
자본화:
|
볼륨(24시간):